Premium
Outcomes of MYC ‐associated lymphomas after R‐ CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704
Author(s) -
Puvvada Soham D.,
Stiff Patrick J.,
Leblanc Michael,
Cook James R.,
Couban Stephen,
Leonard John P.,
Kahl Brad,
Marcellus Deborah,
Shea Thomas C.,
Winter Jane N.,
Li Hongli,
Rimsza Lisa M.,
Friedberg Jonathan W.,
Smith Sonali M.
Publication year - 2016
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.14100
Subject(s) - vincristine , chop , rituximab , medicine , cyclophosphamide , autologous stem cell transplantation , lymphoma , prednisolone , stem cell , oncology , immunology , chemotherapy , biology , genetics
Summary Double hit lymphoma ( DHL ) and double protein‐expressing ( MYC , BCL 2) lymphomas ( DPL ) fare poorly with R‐ CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone); consolidative autologous stem cell transplant ( ASCT ) may improve outcomes. S9704, a phase III randomized study of CHOP +/−R with or without ASCT enabled evaluation of intensive consolidation. Immunohistochemistry ( IHC ) identified 27 of 198 patients (13·6%) with MYC overexpression; 20 (74%) harboured concurrent BCL 2 overexpression. Four had DHL and 16 had DPL only. With median 127 months follow‐up, there is a trend favouring outcomes after ASCT in DPL and MYC protein overexpressing patients, whereas all DHL patients have died irrespective of ASCT .